Cogent Biosciences, Inc. — Director's Dealing 2018

Mar 29, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Unum Therapeutics, Inc. (UMRX)
CIK: 0001622229
Period of Report: 2018-03-28

Reporting Person: Ferrante Karen Jean (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$12.00	2028-03-16	Common Stock (28661)		Direct

Footnotes

F1: The shares shall vest in 36 equal monthly installments beginning on March 28, 2018, subject to the Reporting Persons continuous service with the Issuer.